Edition:
United States

Ignyta Inc (RXDX.OQ)

RXDX.OQ on NASDAQ Stock Exchange Capital Market

9.15USD
3:03pm EST
Change (% chg)

$0.35 (+3.98%)
Prev Close
$8.80
Open
$8.95
Day's High
$9.20
Day's Low
$8.90
Volume
31,910
Avg. Vol
53,785
52-wk High
$9.70
52-wk Low
$4.15

RXDX.OQ

Chart for RXDX.OQ

About

Ignyta, Inc. is an oncology biotechnology company. The Company focuses on an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Its Rx is focused on discovering, in licensing or acquiring, then developing and commercializing molecularly targeted therapies that, sequentially or in... (more)

Overall

Beta: --
Market Cap(Mil.): $366.55
Shares Outstanding(Mil.): 41.65
Dividend: --
Yield (%): --

Financials

  RXDX.OQ Industry Sector
P/E (TTM): -- 44.07 29.88
EPS (TTM): -3.36 -- --
ROI: -69.33 -3.76 13.08
ROE: -92.26 5.68 14.24

BRIEF-Ignyta's updated Phase 1 data on safety, anti-tumor activity published in Cancer Discovery

* Ignyta's updated Phase 1 data on safety, anti-tumor activity and CNS activity of entrectinib in cancers with TRK, ROS1 or ALK fusions published in Cancer Discovery

Feb 09 2017

BRIEF-Ignyta announces EAP Designation and CE Marking for its Trailblaze Pharos clinical trial assay

* Ignyta announces EAP Designation and CE Marking for its Trailblaze Pharos(TM) clinical trial assay Source text for Eikon: Further company coverage:

Nov 15 2016

BRIEF-Ignyta Q3 loss per share $0.56

* Says did not record any revenue for three months ended Sept 30, 2016

Nov 07 2016

More From Around the Web

Earnings vs. Estimates